- Insulet Corporation (PODD, Financial) to highlight Omnipod® 5 outcomes at ADA 85th Scientific Sessions.
- Presentations include evidence from SECURE-T2D and RADIANT trials.
- Innovative booth activities to engage healthcare providers and attendees.
Insulet Corporation (PODD), a leader in tubeless insulin pump technology, is set to showcase the impact of its Omnipod® 5 Automated Insulin Delivery System at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions. The event will take place from June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
The company's presentations and panel discussions will delve into the clinical outcomes from the SECURE-T2D and RADIANT trials, providing valuable insights into the improved health outcomes for individuals with diabetes using the Omnipod® 5 system. Real-world evidence will be shared, drawing from the experiences of over 23,000 people with type 2 diabetes in the United States.
Dr. Trang Ly, Senior Vice President and Chief Medical Officer of Insulet, expressed enthusiasm about the opportunity to present these findings, emphasizing the importance of sharing practical insights with healthcare providers to optimize diabetes therapy.
Key presentations include a panel discussion led by Dr. Ly on June 22, discussing the simplicity and remarkable results achieved with Omnipod 5. Other notable presentations include real-world glycemic outcomes and reduced diabetes distress analysis from the SECURE-T2D study, as well as improved outcomes from the RADIANT study, comparing the Omnipod 5 system to traditional multiple daily injections.
In addition to presentations, the Insulet booth will feature immersive experiences and hands-on demonstrations led by clinical experts. Attendees can participate in educational activities and explore how Omnipod® 5 is revolutionizing diabetes management.
Insulet Corporation, headquartered in Acton, Massachusetts, remains committed to simplifying life with diabetes through its innovative Omnipod product platform, offering reliable, tubeless insulin delivery systems.
